109181 ⎘
Structure or type of the nucleic acid; Chemical structure of the base; Modified C 5-Methylcytosine
REVERSIR TM COMPOUNDS
#302Modulation of GYS1 expression
#303Therapeutic compositions for treating pain via multiple targets
#304PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES
#305OLIGONUCLEOTIDE
#306ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A RETAINED INTRONS
#307Compounds and Methods for Use in Dystrophin Transcript
#308COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS
#309COMPOUNDS AND METHODS FOR MODULATION OF SMN2
#310METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#311MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#312COMPOUNDS AND METHODS FOR MODULATING SMN2
#313Compounds and methods for reducing ATXN3 expression
#314Compounds and methods for modulating PLP1
#315METABOLIC BENEFITS OF SHORT MIR-22 MIRNA ANTAGOMIR THERAPIES
#316MODULATORS OF IRF5 EXPRESSION
#317ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#318Compositions and their uses directed to huntingtin
#319INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#320ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9
#321NEUROFILAMENT PROTEIN FOR GUIDING THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS
#322POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#323Compounds and methods for reducing prion expression
#324CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#325POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF
#326METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
#327Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#328POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
#329Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#330COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#331Compositions and methods for detection of SMN protein in a subject and treatment of a subject
#332Oligonucleotide agonists targeting progranulin
#333Methods and Compositions for the ADAR-Mediated Editing of SERPINA1
#334OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
#335COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
#336GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#337Allele specific modulators of P23H rhodopsin
#338Methods for reducing LRRK2 expression
#339Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof
#340Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
#341POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#342Compounds and Methods for Modulation of Transcript Processing
#343Oligonucleotides targeting frataxin and related methods
#344Long double-stranded RNA for RNA interference
#345Compositions and methods for modulating PKK expression
#346Compounds and methods for modulating UBE3A-ATS
#347Compounds and methods for the modulation of proteins
#348RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
#349ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1
#350LINKAGE MODIFIED OLIGOMERIC COMPOUNDS
#351Compounds and methods for increasing STMN2 expression
#352Antisense oligonucleotides and their use for treating Pendred syndrome
#353Selective antisense compounds and uses thereof
#354Engineered Nucleic Acids and Methods of Use Thereof
#355Compositions for Modulating C9ORF72 Expression
#356POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
#357COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#358Compositions and methods for modulating growth hormone receptor expression
#359ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#360MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#361MODULATORS OF ENaC EXPRESSION
#362SYNTHETIC RNAS AND METHODS OF USE
#363Oligonucleotides comprising modified nucleosides
#364METHODS OF MODULATING ANTISENSE ACTIVITY
#365Immunostimulatory compositions
#366Modulation of factor 11 expression
#367POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#368Modulators of EZH2 expression
#369Methods for treating multiple sclerosis using antisense oligonucleotides
#370OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#371REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
#372Selective Antisense Compounds and Uses Thereof
#373Modulation of Huntington expression
#374COMPOSITIONS AND METHODS
#375POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#376MODULATORS OF GROWTH HORMONE RECEPTOR
#377TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
#378RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#379COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF
#380Modified oligonucleotides for use in treatment of tauopathies
#381Modulation of transthyretin expression
#382OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
#383Compositions and methods for modulating apolipoprotein (a) expression
#384Modulation of alpha synuclein expression
#385Modulation of frataxin expression
#386Modulators of APOL1 expression
#387Inhibition of mir-22 miRNA by APT-110
#388Antisense oligonucleotide compositions
#389Modulators of PCSK9 expression
#390Compositions for modulating Tau expression
#391Oligomers and oligomer conjugates
#392CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#393Compositions and methods for modulation of SMN2 splicing in a subject
#394COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#395COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#396Methods and compositions for modulating apolipoprotein (a) expression
#397Methods for modulating FMR1 expression
#398Selective antisense compounds and uses thereof
#399ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#400MODULATORS OF DNM2 EXPRESSION
#401Conjugated antisense compounds and their use
#402METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#403Immunostimulatory oligonucleotides
#404Anti-C9ORF72 oligonucleotides and related methods
#405MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
#406OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION
#407POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#408COMPANION DIAGNOSTIC FOR HTRA1 RNA ANTAGONISTS
#409Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#410Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#411Compositions for modulating SOD-1 expression
#412RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci
#413Oligonucleotides for inducing paternal UBE3A expression
#414ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
#415EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#416Compositions and methods for modulating Ataxin 3 expression
#417Compositions and their uses directed to huntingtin
#418CANCER TREATMENT
#419Combinations for the modulation of SMN expression
#420Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#421Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof
#422METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#423ANTISENSE COMPOUNDS
#424Single-Stranded RNAI Oligonucleotides Targeting APOC-III
#425Modulation of huntingtin expression
#426POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#427METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION
#428Compositions for modulating expression of C9ORF72 antisense transcript
#429COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION
#430COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#431Antisense Compounds and Uses Thereof
#432ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION
#433Modulators of IRF5 expression
#434Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#435Compounds and methods for reducing Tau expression
#436Modulators of PCSK9 expression
#437METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
#438MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#439Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#440COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#441Multiplex Guide RNAS
#442COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#443ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#444METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#445MODULATORS OF COMPLEMENT FACTOR B
#446RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
#447Compositions and methods for modulating growth hormone receptor expression
#448Modulation of angiopoietin-like 3 expression
#449POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#450Therapeutic uses and methods
#451Methods and compositions for managing vascular conditions
#452MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#453Compositions for modulating Ataxin 2 expression
#454Allele specific modulators of P23H rhodopsin
#455Oligonucleotides for inducing paternal UBE3A expression
#456SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#457COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
#458COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#459Compositions and methods for the treatment of hypercholesterolemia
#460Compositions for modulating SOD-1 expression
#461Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#462Methods for treating Alzheimer's disease
#463RNA containing modified nucleosides and methods of use thereof
#464Oligomers and oligomer conjugates
#465Oligonucleotides for modulating ATXN2 expression
#466MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#467Modulation of Factor 11 expression
#468Permanent gene correction by means of nucleotide-modified messenger RNA
#469ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION
#470Compositions for modulating C9ORF72 expression
#471Conjugated antisense compounds and their use
#472OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
#473Modulators of APOL1 expression
#474ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELB EXPRESSION
#475ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB2 EXPRESSION
#476METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#477Modulation of Lnc05 expression
#478MODULATION OF TMPRSS6 EXPRESSION
#479ANTISENSE OLIGONUCLEOTIDES FOR MODULATING REL EXPRESSION
#480METHODS AND COMPOSITIONS FOR TREATING A SUBJECT WITH A SMAD7 ANTISENSE OLIGONUCLEOTIDE
#481SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#482COMPOUNDS AND METHODS FOR USE IN DYSTROPHIN TRANSCRIPT
#483ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#484Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#485COMPOUNDS AND METHODS FOR MODULATION OF SMN2
#486COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING
#487Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
#488Oligonucleotides for inducing paternal UBE3A expression
#489MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#490Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#491CAMK2D antisense oligonucleotides and uses thereof
#492Compositions for modulating C9ORF72 expression
#493Antisense oligomers targeting HOXB-AS3 long non-coding RNA
#494ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
#495Modulation of huntingtin expression
#496Compounds and methods for reducing ATXN3 expression
#497Engineered guide RNA and uses thereof
#498Modulators of DNM2 expression
#499Modulation of prekallikrein (PKK) expression
#500MODULATORS OF GROWTH HORMONE RECEPTOR
#501Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof
#502Neutral nanotransporters
#503Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#504COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#505Modulation of GYS1 expression
#506MIR-92 INHIBITORS AND USES THEREOF
#507RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
#508Oligonucleotides comprising modified nucleosides
#509MODULATION OF TRANSTHYRETIN EXPRESSION
#510Reduced size self-delivering RNAI compounds
#511MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF
#512Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#513Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
#514GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
#515MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#516SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III
#517In vivo gene silencing by chemically modified and stable siRNA
#518Modulation of DYRK1B expression
#519Modulation of angiopoietin-like 3 expression
#520Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#521Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#522Methods and compositions for inhibiting PMP22 expression
#523COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#524MODULATORS OF COMPLEMENT FACTOR B
#525Aptamers for consumer product compositions
#526Identification of genetic modifications
#527PLANT GENOME MODIFICATION USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS AND METHODS OF USE
#528MODULATORS OF KLK3 ERNA
#529Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
#530Oligonucleotides
#531Methods for modulating Ataxin 2 expression
#532Compositions and methods for modulating angiopoietin-like 3 expression
#533SELECTIVE REDUCTION OF ALLELIC VARIANTS
#534PLANT GENOME MODIFICATION USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS AND METHODS OF USE
#535Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
#536RNA interference in dermal and fibrotic indications
#537Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#538Methods for reducing LRRK2 expression
#539Targeted augmentation of nuclear gene output
#540Methods and compositions for managing vascular conditions
#541RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#542Mobilizing leukemia cells
#543Cancer treatment
#544Compositions and their uses directed to huntingtin
#545RNA interference in skin indications
#546Argonaute protein-double stranded RNA complexes and uses related thereto
#547COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#548MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
#549COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE
#550MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#551Targeting MicroRNAs for the Treatment of Fibrosis
#552COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#553TLR MODULATORS AND METHODS OF USE
#554Compositions and methods for modulating apolipoprotein (a) expression
#555Compositions and methods for modulating apolipoprotein C-III expression
#556MODULATION OF TRANSTHYRETIN EXPRESSION
#557MODULATION OF TRANSTHYRETIN EXPRESSION
#558Compositions and their uses directed to huntingtin
#559Modulation of SMN expression
#560MODULATORS OF KRAS EXPRESSION
#561PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
#562Compositions and methods for modulating Ataxin 3 expression
#563Conjugated antisense compounds and their use
#564Methods and compositions for modulating apolipoprotein (a) expression
#565Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
#566COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#567MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#568MiR-92 inhibitors and uses thereof
#569Methods and compositions for modlating apolipoprotein (A) expression
#570METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#571Modulation of TMPRSS6 expression
#572Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
#573Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
#574Micromirs
#575OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
#576MODULATION OF TRANSTHYRETIN EXPRESSION
#577MODULATION OF TRANSTHYRETIN EXPRESSION
#578MODULATION OF TRANSTHYRETIN EXPRESSION
#579MODULATION OF TRANSTHYRETIN EXPRESSION
#580MODULATION OF TRANSTHYRETIN EXPRESSION
#581MODULATION OF TRANSTHYRETIN EXPRESSION
#582MODULATION OF TRANSTHYRETIN EXPRESSION
#583MODULATION OF TRANSTHYRETIN EXPRESSION
#584MODULATION OF TRANSTHYRETIN EXPRESSION
#585MODULATION OF TRANSTHYRETIN EXPRESSION
#586Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
#587Allele specific modulators of P23H rhodopsin
#588Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof
#589MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#590Compounds and methods for increasing antisense activity
#591MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#592Methods for modulating expression of C9ORF72 antisense transcript
#593Modulation of nuclear-retained RNA
#594Targeting microRNAs for the treatment of liver cancer
#595Compounds and methods for reducing Tau expression
#596Compositions for modulating expression of C9ORF72 antisense transcript
#597Engineered Nucleic Acids and Methods of Use Thereof
#598Inhibitors of MYH7B and uses thereof
#599Compositions for modulating Tau expression
#600EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS